Immunological basis of systemic sclerosis

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Zuber, Jean Philippe ^a   Spertini, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CD19 ANTIGEN; CENTROMERE ANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; DNA; ENDOTHELIAL CELL ANTIBODY; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; SCL 70 ANTIBODY; STEROID; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; CYTOKINE PRODUCTION; DNA SEQUENCE; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; LYMPHOCYTIC INFILTRATION; MICROANGIOPATHY; NATURAL KILLER CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; Y CHROMOSOME;

ANTIBODY FORMATION; AUTOANTIBODIES; CHIMERISM; CYTOKINES; FIBROSIS; HUMANS; IMMUNITY, CELLULAR; SCLERODERMA, SYSTEMIC;

EID: 33749014390     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel285     Document Type: Article

References (12)

1. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
2. Prescott RJ FA, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
3. Sakkas LI, Platsoucas C. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50:1721-33.
4. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin-4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
5. Kurosawa K, Hirose K, Sano H et al. Increased IL-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-3.
6. Chizzolini C, Parel Y, De Luca C et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593-604.
7. Valentini G, Baroni A, Esposito K et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001;21:210-7.
8. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59.
9. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated B cells. Arthritis Rheum 2004;50:1918-27.
10. Worda M, Sgouc R, Dietrich H et al. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorioallantonic membrane assay. Arthritis Rheum 2003;48:2605-14.
11. Chizzolini C, Raschi E, Rezzonico R et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13.
12. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998;338:1186-91.